Background/Aims: Accumulation of protein-bound uremic toxins (PBUTs) is associated with mortality due to various systemic disorders in patients with chronic kidney disease (CKD), especially in those undergoing dialysis treatment. The clinical outcomes of such patients could be improved by removing sufficient amounts of PBUTs; however, conventional dialysis lacks this ability. We examined the efficacy of activated carbon in adsorbing circulating PBUTs through direct hemoperfusion (DHP) in vitro. Methods: An in vitro blood circulating system was constructed with 8.5 mL blood circulating around a column containing activated carbon (50, 100, or 200 mg). Bovine blood containing a kind of PBUT (at the same concentration as that found in the blood of dialysis patients) and blood from hemodialysis patients (n = 8) were used. After circulation for the designated amount of time, sera were collected and the levels of PBUTs, including indoxyl sulfate (IS), p-cresyl sulfate, indole acetic acid (IAA), phenyl sulfate, and hippuric acid, were analyzed with mass spectrometry. Results: Activated carbon decreased the PBUT level in bovine blood in a dose-dependent manner (e.g., reduction rate of IS: 67.9 ± 3.8, 83.3 ± 1.9, and 94.5 ± 1.1% after 60-min circulation in columns containing 50, 100, and 200 mg activated carbon respectively). IS, PCS, and IAA were dramatically adsorbed by activated carbon from the blood of patients undergoing hemodialysis (pre vs. post 240-min reaction: IS 2.835 ± 0.876 vs. 0.455 ± 0.108 mg/dL [p < 0.01], PCS 3.208 ± 2.876 vs. 0.768 ± 0.632 mg/dL [p < 0.01], IAA 0.082 ± 0.045 vs. 0.016 ± 0.005 mg/dL [p < 0.01]). Conclusion: Activated carbon effectively adsorbed blood PBUTs in vitro. DHP with activated carbon could be a promising strategy for removing circulating PBUTs from the blood of patients with CKD.

Keywords:
Protein-bound uremic toxins, Direct hemoperfusion, Activated carbons, Hemodialysis
1.
Levey AS, Coresh J. Chronic kidney disease.
Lancet
. 2012 Jan;379(9811):165–80.
2.
Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H. Cardiorenal syndrome: the emerging role of protein-bound uremic toxins.
Circ Res
. 2012 Nov;111(11):1470–83.
3.
Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients.
Kidney Int
. 2006 Mar;69(6):1081–7.
4.
Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al.; European Uremic Toxin Work Group (EUTox). Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.
Clin J Am Soc Nephrol
. 2009 Oct;4(10):1551–8.
5.
Dou L, Sallée M, Cerini C, Poitevin S, Gondouin B, Jourde-Chiche N, et al. The cardiovascular effect of the uremic solute indole-3 acetic acid.
J Am Soc Nephrol
. 2015 Apr;26(4):876–87.
6.
Krieter DH, Hackl A, Rodriguez A, Chenine L, Moragues HL, Lemke HD, et al. Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration.
Nephrol Dial Transplant
. 2010 Jan;25(1):212–8.
7.
Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production.
Anal Bioanal Chem
. 2012 Jun;403(7):1841–50.
8.
Yamamoto S, Kazama JJ, Omori K, Matsuo K, Takahashi Y, Kawamura K, et al. Continuous Reduction of Protein-Bound Uraemic Toxins with Improved Oxidative Stress by Using the Oral Charcoal Adsorbent AST-120 in Haemodialysis Patients.
Sci Rep
. 2015 Sep;5(1):14381.
9.
Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD.
Am J Kidney Dis
. 2006 Apr;47(4):565–77.
10.
Cha RH, Kang SW, Park CW, Cha DR, Na KY, Kim SG, et al. A Randomized, Controlled Trial of Oral Intestinal Sorbent AST-120 on Renal Function Deterioration in Patients with Advanced Renal Dysfunction.
Clin J Am Soc Nephrol
. 2016 Apr;11(4):559–67.
11.
Yamamoto S, Sato M, Sato Y, Wakamatsu T, Takahashi Y, Iguchi A, et al. Adsorption of Protein-Bound Uremic Toxins Through Direct Hemoperfusion With Hexadecyl-Immobilized Cellulose Beads in Patients Undergoing Hemodialysis.
Artif Organs
. 2018 Jan;42(1):88–93.
12.
Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T. Correlation between Serum Levels of Protein-Bound Uremic Toxins in Hemodialysis Patients Measured by LC/MS/MS.
Mass Spectrom (Tokyo)
. 2013;2(Spec Iss):S0017.
13.
Yamamoto S, Zuo Y, Ma J, Yancey PG, Hunley TE, Motojima M, et al. Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice.
Nephrol Dial Transplant
. 2011 Aug;26(8):2491–7.
14.
Fujii H, Nishijima F, Goto S, Sugano M, Yamato H, Kitazawa R, et al. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress.
Nephrol Dial Transplant
. 2009 Jul;24(7):2089–95.
15.
Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Langham RG, Nishijima F, et al.  Chronic kidney disease-induced cardiac -fibrosis is ameliorated by reducing -circulating  levels of a non-dialysable uremic toxin,  indoxyl sulfate.
PLoS One
. 2012; 7(7):e41281.
16.
Iwasaki Y, Kazama JJ, Yamato H, Shimoda H, Fukagawa M. Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease.
Bone
. 2013 Dec;57(2):477–83.
17.
Matsuo K, Yamamoto S, Wakamatsu T, Takahashi Y, Kawamura K, Kaneko Y, et al. Increased Proinflammatory Cytokine Production and Decreased Cholesterol Efflux Due to Downregulation of ABCG1 in Macrophages Exposed to Indoxyl Sulfate.
Toxins (Basel)
. 2015 Aug;7(8):3155–66.
18.
Nii-Kono T, Iwasaki Y, Uchida M, Fujieda A, Hosokawa A, Motojima M, et al. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells.
Kidney Int
. 2007 Apr;71(8):738–43.
19.
Wu IW, Hsu KH, Hsu HJ, Lee CC, Sun CY, Tsai CJ, et al. Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients–a prospective cohort study.
Nephrol Dial Transplant
. 2012 Mar;27(3):1169–75.
20.
Watanabe H, Miyamoto Y, Enoki Y, Ishima Y, Kadowaki D, Kotani S, et al. p-Cresyl sulfate, a uremic toxin, causes vascular endothelial and smooth muscle cell damages by inducing oxidative stress.
Pharmacol Res Perspect
. 2015 Feb;3(1):e00092.
21.
Tanaka H, Iwasaki Y, Yamato H, Mori Y, Komaba H, Watanabe H, et al. p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways.
Bone
. 2013 Oct;56(2):347–54.
22.
Basile C, Libutti P, Di Turo AL, Casino FG, Vernaglione L, Tundo S, et al. Removal of uraemic retention solutes in standard -bicarbonate haemodialysis and long-hour slow-flow bicarbonate haemodialysis.
Nephrol Dial Transplant
. 2011 Apr;26(4):1296–303.
23.
De Smet R, Dhondt A, Eloot S, Galli F, Waterloos MA, Vanholder R. Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes.
Nephrol Dial Transplant
. 2007 Jul;22(7):2006–12.
24.
Pavlenko D, Giasafaki D, Charalambopoulou G, van Geffen E, Gerritsen KG, Steriotis T, et al. Carbon Adsorbents With Dual Porosity for Efficient Removal of Uremic Toxins and Cytokines from Human Plasma.
Sci Rep
. 2017 Nov;7(1):14914.
25.
Neuvonen PJ, Olkkola KT. Oral activated charcoal in the treatment of intoxications. Role of single and repeated doses.
Med Toxicol
. 1988 Jan-Dec;3(1):33–58.
26.
Ahmed MJ. Adsorption of quinolone, tetracycline, and penicillin antibiotics from aqueous solution using activated carbons: review.
Environ Toxicol Pharmacol
. 2017 Mar;50:1–10.
27.
Ahmed MJ. Adsorption of non-steroidal anti-inflammatory drugs from aqueous solution using activated carbons: review.
J Environ Manage
. 2017 Apr;190:274–82.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.